Search Results - "Bovee, Tim D."

Reducing hydrophobicity of homogeneous antibody-drug conjugates improves pharmacokinetics and therapeutic index by Lyon, Robert P, Bovee, Tim D, Doronina, Svetlana O, Burke, Patrick J, Hunter, Joshua H, Neff-LaFord, Haley D, Jonas, Mechthild, Anderson, Martha E, Setter, Jocelyn R, Senter, Peter D

“…The in vivo efficacy of antibody-drug conjugates is enhanced by decreasing their hydrophobicity. The in vitro potency of antibody-drug conjugates (ADCs)…”
Get full text

Development of potent monoclonal antibody auristatin conjugates for cancer therapy by Senter, Peter D, Doronina, Svetlana O, Toki, Brian E, Torgov, Michael Y, Mendelsohn, Brian A, Cerveny, Charles G, Chace, Dana F, DeBlanc, Ron L, Gearing, R Patrick, Bovee, Tim D, Siegall, Clay B, Francisco, Joseph A, Wahl, Alan F, Meyer, Damon L

“…We describe the in vitro and in vivo properties of monoclonal antibody (mAb)-drug conjugates consisting of the potent synthetic dolastatin 10 analogs…”
Get full text

Enhanced Activity of Monomethylauristatin F through Monoclonal Antibody Delivery:  Effects of Linker Technology on Efficacy and Toxicity by Doronina, Svetlana O, Mendelsohn, Brian A, Bovee, Tim D, Cerveny, Charles G, Alley, Stephen C, Meyer, Damon L, Oflazoglu, Ezogelin, Toki, Brian E, Sanderson, Russell J, Zabinski, Roger F, Wahl, Alan F, Senter, Peter D

“…We have previously shown that antibody−drug conjugates (ADCs) consisting of cAC10 (anti-CD30) linked to the antimitotic agent monomethylauristatin E (MMAE)…”
Get full text

Self-hydrolyzing maleimides improve the stability and pharmacological properties of antibody-drug conjugates by Lyon, Robert P, Setter, Jocelyn R, Bovee, Tim D, Doronina, Svetlana O, Hunter, Joshua H, Anderson, Martha E, Balasubramanian, Cindy L, Duniho, Steven M, Leiske, Chris I, Li, Fu, Senter, Peter D

“…A new method for linking antibodies to drugs produces conjugates with improved stability and efficacy. Many antibody-drug conjugates (ADCs) are unstable in…”
Get full text

Novel Auristatins with High Bystander and Cytotoxic Activities in Drug Efflux-positive Tumor Models by Moquist, Philip N, Bovee, Tim D, Waight, Andrew B, Mitchell, Jamie A, Miyamoto, Jamie B, Mason, Marsha L, Emmerton, Kim K, Stevens, Nicole, Balasubramanian, Cindy, Simmons, Jessica K, Lyon, Robert P, Senter, Peter D, Doronina, Svetlana O

“…Auristatins, a class of clinically validated anti-tubulin agents utilized as payloads in antibody-drug conjugates, are generally classified by their membrane…”
Get full text

Novel Peptide Linkers for Highly Potent Antibody−Auristatin Conjugate by Doronina, Svetlana O, Bovee, Tim D, Meyer, David W, Miyamoto, Jamie B, Anderson, Martha E, Morris-Tilden, Carol A, Senter, Peter D

“…Auristatins are highly potent antimitotic agents that have received considerable attention because of their activities when targeted to tumor cells in the form…”
Get full text

Abstract 2803: Novel auristatins with high activity on efflux-positive models and demonstrable bystander activity by Moquist, Philip N., Bovee, Tim D., Waight, Andrew B., Owen, Sarah, Mitchell, Jamie A., Zaval, Margo, Quick, Marsha, Sandall, Sharsti, Emmerton, Kim K., Blesie, Nicole, Lyon, Robert P., Senter, Peter, Doronina, Svetlana

“…Abstract Auristatins are a class of clinically validated antimitotic agents utilized as payloads in antibody-drug conjugates (ADCs). Auristatins display many…”
Get full text

Abstract 4470: Elucidating the role of drug-linker hydrophobicity in the disposition of antibody-drug conjugates by Doronina, Svetlana O., Setter, Jocelyn R., Bovee, Tim D., Anderson, Martha E., Jonas, Mechtild, Daniho, Steven, Kostner, Heather, Senter, Peter D., Lyon, Robert P.

“…Abstract The in vitro potency of antibody-drug conjugates (ADCs) is generally proportional to the level of drug loading, with higher drug per antibody levels…”
Get full text

Abstract 4333: Self-stabilizing ADCs: antibody-drug conjugates prepared with maleimido drug-linkers that catalyze their own thiosuccinimide ring hydrolysis by Lyon, Robert P., Setter, Jocelyn R., Bovee, Tim D., Doronina, Svetlana O., Anderson, Martha E., Leiske, Chris L., Senter, Peter D.

“…Abstract Many antibody-drug conjugates (ADCs) currently in clinical trials employ maleimide-containing drug-linkers which are conjugated to antibody cysteine…”
Get full text

Abstract 2831: Novel antibody-drug conjugates for selective tumor activation by Setter, Jocelyn R., Doronina, Svetlana O., Bovee, Tim D., Anderson, Marti E., Senter, Peter D., Benjamin, Dennis R., Lyon, Robert P.

“…Abstract Auristatin based antibody-drug conjugates (ADCs) have demonstrated profound activites, both preclinically and clinically. Upon internalization, the…”
Get full text

Erratum: Development of potent monoclonal antibody auristatin conjugates for cancer therapy by Doronina, Svetlana O, Toki, Brian E, Torgov, Michael Y, Mendelsohn, Brian A, Cerveny, Charles G, Chace, Dana F, DeBlanc, Ron L, Gearing, R Patrick, Bovee, Tim D, Siegall, Clay B, Francisco, Joseph A, Wahl, Alan F, Meyer, Damon L, Senter, Peter D

Get full text

Development of potent monoclonal antibody auristatin conjugates for cancer therapy by Doronina, Svetlana O, Toki, Brian E, Torgov, Michael Y, Mendelsohn, Brian A, Cerveny, Charles G, Chace, Dana F, DeBlanc, Ron L, Gearing, R Patrick, Bovee, Tim D, Siegall, Clay B, Francisco, Joseph A, Wahl, Alan F, Meyer, Damon L, Senter, Peter D

Get full text